Investing4d
IDEAYA Biosciences' SWOT analysis: cancer therapy stock poised for pivotal year
IDEAYA Biosciences, Inc. (NASDAQ:IDYA), a biotechnology company specializing in targeted therapies for cancer, is positioning itself for a transformative year in 2025. Currently trading near its ...
Investing4d
IDEAYA Biosciences' SWOT analysis: cancer therapy stock poised for pivotal year
IDEAYA Biosciences, Inc. (NASDAQ:IDYA), a biotechnology company specializing in targeted therapies for cancer, is positioning itself for a transformative year in 2025. Currently trading near its ...
ETF Daily News5d
Brokers Issue Forecasts for IDYA FY2029 Earnings
IDEAYA Biosciences, Inc. (NASDAQ:IDYA – Free Report) – Analysts at Wedbush issued their FY2029 EPS estimates for IDEAYA Biosciences in a research report issued to clients and investors on ...
Yahoo Finance2d
IDEAYA Biosciences, Inc. (IDYA)
After hours: February 11 at 6:01:26 p.m. EST ...
BioSpace3d
Uveal Melanoma Market Size to Reach USD 1,600 Million by 2035, Impelled by Technological Advancements in Personalized Medicine.
Darovasertib - Ideaya Biosciences Darovasertib, developed by Ideaya Biosciences, is an investigational targeted therapy for uveal melanoma. It is a PKC (protein kinase C) inhibitor aimed at inhibiting ...
Gilead upgraded to Buy from Hold at Deutsche Bank
Deutsche Bank upgraded Gilead (GILD) to Buy from Hold with a $120 price target Discover the Best Stocks and Maximize Your Portfolio: See what ...
BioSpace4d
After 10 Years of Hard Work, COUR Treads Into Pharma’s Myasthenia Gravis Territory
COUR Pharmaceuticals has been around a while, but not until last year did the company solidify behind its ultimate mission with a series A raise. It took COUR Pharmaceuticals a full decade before ...